Company Overview and News
The Cooper Companies (COO - Free Report) recently announced four-year study results which show that its CooperVision (CVI) MiSight can significantly check juvenile myopia progression. Notably, the lens is commercially available in select countries. The latest development is likely to aid the company’s core CVI segment.
MASI COO TXN MDPEB ISRG MDP ATHN
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Becton, Dickinson (BDX), Occidental Petroleum (OXY) and Phillips 66 (PSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
DB PSX UMBF BRK.A COO ALL STI STI-A OXY
2018-09-04 seekingalpha - 1
The top three positions are Henry Schein, Dentsply Sirona, and Cooper Companies and they add up to ~23% of the entire portfolio.
JD BAP TXN TMO ADP GOOG CRM AYI.WI COO NKE AMZN IR CERN MELI AYI WSBF WSCC MA INFY MCHP HSIC CMG MULE V XRAY ADPVV GOOGL ADI INFY JLL WAT MSFT APTV
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
The Cooper Companies (COO - Free Report) reported third-quarter fiscal 2018 earnings of $3.00 per share, missing the Zacks Consensus Estimate by 2.6%. However, earnings increased 13.6% on a year-over-year basis.
COO RSG ISRG ILMN
2018-08-30 sec.gov - 1
PLEASANTON, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal third quarter ended July 31, 2018.
Intuitive Surgical, Inc (ISRG - Free Report) is currently a top performer in the MedTech space. Improved price performance, better-than-expected earnings results, significant exposure to Artificial Intelligence (AI) trends in healthcare and strong fundamentals instill investors’ optimism in the stock.
COO HD INGN PSTG HEAR ISRG OXY
On Aug 14, we issued an updated research report on CVS Health (CVS - Free Report) . While increasing demand for PBM (Pharmacy Benefit Management) and specialty pharmacy was a major growth driver for the stock, its dull retail performance over the last few quarters seems to have disappointed investors. The company carries a Zacks Rank #3 (Hold).
COO HD INGN CVS OXY
On Aug 13, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART - Free Report) . The company has been witnessing certain major developments overseas. However, a tough competitive landscape raises concerns.
COO INGN IART
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to COO / Cooper Companies, Inc. (The) on message board site Silicon Investor.
as of ET